SNY
Sanofi
Nasdaq: SNY · Paris, I0 · Healthcare
$41.60-0.36 (-0.86%)Closed
Market Cap$50.73B
Cash—most recent
Runway—
P/E (TTM)—
52-Wk Range$39.12 – $49.59
Avg Volume3.2M3-month
Price & Trading Activity

Daily close with catalyst overlays and trading volume

$41.60-11.9%
Pipeline

Drug candidates sponsored by Sanofi · ClinicalTrials.gov

93 drugs · 100 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 4Insuline glargine
Diabetes Mellitus, Type 2
Terminated
2007-06past
1
Phase 4clopidogrel (SR25990C)
Cerebral Infarction
Completed
2008-12past
1
Phase 4LACTIC ACID(ND)
Hygiene
Completed
2009-03past
1
Phase 4Coarsucam
Malaria
Completed
2010-06past
1
Phase 4Influenza Virus Vaccine: Fluzone® 2011-2012 Formulation
Influenza
Completed
2012-02past
1
Phase 4INSULIN GLARGINE
Diabetes Mellitus, Type 2+1 more
Completed
2012-07past
2
Phase 4Granulocyte-colony stimulating factor (G-CSF)
Non-Hodgkin's Lymphoma
Completed
2013-02past
1
Phase 4300mg vandetanib
Thyroid Cancer
Completed
2014-04-02past
1
Phase 4Meningococcal polysaccharide diphtheria toxoid conjugate
Meningitis+5 more
Completed
2014-11past
1
Phase 4Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation
Influenza
Completed
2014-12past
1
Phase 4Teriflunomide
Multiple Sclerosis
Completed
2015-11past
1
Phase 4Fluzone® Quadrivalent Influenza Vaccine, No Preservative
Influenza
Completed
2015-12past
1
Phase 4Irbesartan/atorvastatin fixed dose combination
Type 2 Diabetes Mellitus
Completed
2018-04-19past
1
Phase 4INSULIN GLARGINE (HOE901)
Type 2 Diabetes Mellitus
Completed
2020-06-29past
1
Phase 4Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2020-2021 formulation
Influenza Immunization+1 more
Completed
2020-12-18past
1
Phase 4Dupilumab SAR231893
Dermatitis Atopic
Completed
2022-09-07past
1
Phase 4Cerezyme® / Imiglucerase
Gaucher's Disease
Completed
2023-10-12past
1
Phase 4iGlarLixi (insulin glargine/lixisenatide)
Type 2 Diabetes
Completed
2026-06-12past
1
Phase 4Nirsevimab
RSV Immunization
Active, not recruiting
2026-06-30past
1
Phase 4Hyalgan (sodium hyaluronate)
Osteoarthritis
Completed—1
Phase 4zolpidem tartrate
Insomnia
Completed—1
Phase 3Rimonabant (SR141716)
Obesity+1 more
Completed
2003-11past
1
Phase 3Aldurazyme
Mucopolysaccharidosis I+3 more
Completed
2005-03past
1
Phase 3XRP6976 (Docetaxel/Taxotere)
Cancer
Completed
2006-02past
1
Phase 3Ciclesonide (XRP1526)
Asthma
Completed
2006-02past
1
Phase 3Telithromycin (HMR3647)
Tonsillitis+1 more
Terminated
2006-08past
1
Phase 3Saredutant succinate (SR48968C)
Depressive Disorder
Completed
2006-12past
1
Phase 3Insulin glulisine
Diabetes Mellitus, Type 1
Completed
2007-12past
1
Phase 3Lactic acid (Dermacid)
Hygiene+1 more
Completed
2008-02past
2
Phase 3Dermacyd PH_DETINLYN (Lactic Acid)
Hygiene
Completed
2008-09past
1
Phase 3Satavaptan
Ascites+1 more
Terminated
2008-10past
1
Phase 3Metformin
Type 2 Diabetes Mellitus
Completed
2010-03past
1
Phase 2Docetaxel, Cisplatin, 5-fluorouracil (5-FU), radiotherapy
Head and Neck Neoplasms
Completed
2010-07past
1
Phase 3Ramipril
Glomerulonephritis
Completed
2010-09past
1
Phase 3Meningococcal Polysaccharide Diphtheria Toxoid Conjugate (Menactra®)
Meningococcal Infection+1 more
Completed
2011-02past
1
Phase 3Concomitant administration
Diphtheria+3 more
Completed
2011-09past
1
Phase 3clofarabine (IV formulation)
Acute Myelogenous Leukemia+6 more
Completed
2012-01past
2
Phase 3Purified inactivated rabies vaccine, serum free
Rabies+1 more
Completed
2012-03past
1
Phase 3Eliglustat tartrate
Gaucher Disease, Type 1
Completed
2012-07past
1
Phase 3Cabazitaxel (XRP6258)
Prostate Cancer+1 more
Completed
2015-09past
4
Phase 3Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell
Cholera
Completed
2015-09past
1
Phase 3Insulin aspart
Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus
Completed
2018-07-16past
1
Phase 3Insulin glargine (U300)
Type 2 Diabetes Mellitus
Completed
2018-08-06past
1
Phase 3Insulin glargine/Lixisenatide
Type 2 Diabetes Mellitus
Terminated
2019-01-07past
1
Phase 3Caplacizumab
Thrombotic Thrombocytopenic Purpura
Completed
2024-12-26past
1
Phase 3avalglucosidase alfa
Glycogen Storage Disease Type II
Active, not recruiting
2026-03-02past
1
Phase 3efanesoctocog alfa (BIVV001)
Hemophilia A
Active, not recruiting
2027-01-15
1
Phase 2SL77.0499-10 (alfuzosin hydrochloride)
Benign Prostatic Hyperplasia
Completed
2005-08past
1
Phase 2DOCETAXEL(XRP6976)
Head and Neck Neoplasms
Completed
2005-11past
1
Phase 2Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 1)
Influenza+1 more
Completed
2008-06past
1
Phase 2SSR180711C
Alzheimer's Disease
Terminated
2008-07past
1
Phase 2AVE1625
Schizophrenia
Terminated
2009-09past
1
Phase 2CYD Dengue Vaccine Serotypes 1, 2, 3, and 4
Dengue Virus+3 more
Completed
2010-02-16past
1
Phase 1XL147 (SAR245408)
Breast Cancer
Completed
2013-04past
1
Phase 2DOCETAXEL (XRP6976)
Prostate Cancer Metastatic
Completed
2015-08past
1
Phase 2ALX-0171 3.0 mg/kg
Respiratory Syncytial Virus Lower Respiratory Tract Infection
Completed
2018-05-25past
1
Phase 1Tesevatinib
Polycystic Kidney, Autosomal Dominant
Completed
2019-02-08past
1
Phase 1SARS-CoV-2 mRNA vaccine formulation 1
COVID-19
Terminated
2022-06-27past
1
Phase 2SAR443122
Cutaneous Lupus Erythematosus
Completed
2023-05-25past
1
Phase 2SAR441344
Sjögren's Syndrome+1 more
Completed
2023-11-08past
1
Phase 1Quadrivalent Influenza mRNA Vaccine MRT5413
Influenza Immunization
Completed
2024-04-02past
1
Phase 2Belumosudil 200 mg QD
Chronic Graft-versus-host-disease
Completed
2024-06-06past
1
Phase 2SAR442501
Osteochondrodysplasia
Terminated
2025-02-12past
1
Phase 2BIVV020 (SAR445088)
Transplant Rejection
Active, not recruiting
2025-10-21past
1
Phase 1SAR444200
Neoplasm
Terminated
2025-12-22past
1
Phase 2lunsekimig
Chronic Rhinosinusitis With Nasal Polyps+1 more
Completed
2026-02-23past
2
Phase 1RIV (recombinant influenza vaccine)
COVID-19 Immunization+1 more
Completed
2026-04-03past
1
Phase 2Dupilumab
Colitis Ulcerative
Active, not recruiting
2026-05-13past
1
Phase 2brivekimig
Crohn's Disease
Recruiting
2026-12-17
1
Phase 2Isatuximab SC-OBDS
Plasma Cell Myeloma Refractory
Recruiting
2027-01-08
1
Phase 2SAR445419
Allogenic Stem Cell Transplantation
Withdrawn
2027-02-12
1
Phase 2SAR445399
Hidradenitis Suppurativa
Recruiting
2027-09-22
1
Phase 2Clopidogrel (SR25990)
Congenital Heart Defects+1 more
Completed—1
Phase 2Mitoguazone
Lymphoma, Non-Hodgkin+1 more
Completed—1
Phase 2ZD6474
Non-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line
Completed—1
Phase 1AMD3100
Acute Myelogenous Leukemia+1 more
Withdrawn—1
Phase 2Oxaliplatin, Paclitaxel
Neoplasms, Germ Cell and Embryonal
Completed—1
Phase 1Vaccine diluent buffer
Clostridium Difficile Infection+1 more
Terminated
2006-06past
1
Phase 1ZD6474 (Vandetanib)
Non-small Cell Lung Cancer (NSCLC)
Terminated
2010-08past
1
Phase 1Pneumococcal Vaccine Formulation 1
Pneumococcal Infections+2 more
Completed
2010-09past
1
Phase 1Unnamed
Healthy
Completed
2011-06past
1
Phase 1PF-05230905
Healthy
Completed
2011-11past
1
Phase 1Alirocumab (Solution)
Hypercholesterolemia
Completed
2012-01past
1
Phase 1ALX-0651
Healthy Volunteers
Terminated
2012-01past
1
Phase 1Sotagliflozin (SAR439954)
Diabetes Mellitus
Completed
2017-09-15past
1
Phase 1Amcenestrant (SAR439859)
Breast Cancer
Terminated
2020-10-27past
1
Phase 1amcenestrant
Hepatic Function Abnormal
Terminated
2022-05-16past
1
Phase 1SAR444336
Healthy Volunteer
Completed
2023-12-12past
1
Phase 1SAR439459
Osteogenesis Imperfecta
Terminated
2024-11-12past
1
N/ADocetaxel
Ovarian Neoplasms
Completed
2010-11past
1
N/ADTaP-IPV/Hib
Diphtheria+3 more
Completed
2014-08past
1
N/AUnnamed
Type 2 Diabetes Mellitus
Completed
2024-06-18past
1
N/ALeflunomide
Rheumatoid Arthritis+1 more
Completed
2026-05-14past
1
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

No peer cohort defined for SNY. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.